Fusion energy, the process of fusing light atomic nuclei to generate energy, has long been considered the key to a clean and ...

The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, TRKA, TRKB, and TRKC inhibitor. The report provides product descriptions, ...

Singular Genomics Systems (NASDAQ:OMIC – Get Free Report) will likely be issuing its quarterly earnings data after the market ...

Interestingly, it has been observed that chimeric fusion genes sometimes involve two copies of the same gene (e.g., the alcohol dehydrogenase gene in Drosophila), and when that happens ...

We have investigated the prediction of protein interactions through the analysis of domain fusion to assess whether metabolic enzymes have a higher participation in gene-fusion events compared ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

gene fusion who have disease progression on or after prior systemic therapy. “This manuscript provides comprehensive data on the safety and efficacy of Bizengri ® and demonstrates the meaningful ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...